New Clinical Trials

• Swedish Medical Center
• ACTU
• Proyecto Positivamente Latino

Swedish Medical Center

HIV Research Study at Swedish Medical Center

The Swedish Research Center is currently studying the safety and effectiveness of an investigational formulation of marketed HIV drugs when given in combination with other HIV drugs to people who are HIV positive. To qualify you must be 18 years of age or older, HIV positive, but have not taken anti-HIV medications before.

Qualified participants will receive all study-related care at no cost, including:

• Study medications
• Lab tests
• Physical exams

Reimbursement for childcare and transportation is also available. For more information and/or to find out if you qualify for this study, please contact Janice Price, R.N., at (206) 386-2523.

ACTU

HIV Research Study at the AIDS Clinical Trials Unit

University of Washington
AIDS Clinical Trials Unit
actu@u.washington.edu
http://depts.washington.edu/actu
En Español: joaquinp@u.washington.edu

Latest Studies, Winter 2003

(ACTG # 5117) Comparing the efficacy of adefovir and tenofovir for the treatment of lamivudine-resistant hepatitis B in subjects co-infected with HIV.

Purpose: The study has two purposes 1) to see if adding adefovir or tenofovir with lamividune is effective in treating hepatitis B, 2) and to see if these drugs are safe and well tolerated. The study is expected to run for about 2+ years and it offers exams, medications, and lab tests at no costs. $20 reimbursement per visit to those who enrolled.

(ACTG # 5115) Antiretroviral switch at lower versus higher HIV-RNA levels in subjects experiencing virologic relapse on current HAART treatment.

Purpose: A study to find out if it is better to change medications as soon as a viral load is at or below 200 (barely detectable with current tests), or whether it is better to wait until the viral load is higher. Changing medications at different viral loads levels might matter in terms of:

• The immune system's ability to repair itself even when the HIV viral load is not completely suppressed.
• Whether HIV is more or less likely to develop resistance if changes in medications are delayed. (Resistance is determined when some of the anti-HIV medications included in a regimen no longer work as well against the HIV virus.)

For more information about these studies call 206.731.3184 and ask to speak with Alyssa or Lori.

Proyecto Positivamente Latino

Universidad de Washington
Unidad de Estudios Clínicos de SIDA

Estudios Recientes Invierno 2003

(ACTG # 5117) Comparando la eficacia de adefovir y tenofovir para el tratamiento de hepatitis B resistente a lamividune en sujetos con co-infección de VIH.

Propósito: El estudio tiene dos propósitos: 1) ver si la adición de adefovir o tenofovir con lamivudine es efectiva para el tratamiento de hepatítis B. 2) ver si estos medicamentos son seguros y se toleran bien. El estudio durará aproximadamente 2 años y ofrece examenes, medicamentos y pruebas de laboratorio sin costo. $20 como compensación a todos los que participen en el estudio.

(ACTG # 5115) Cambio de antiretrovirales con carga viral baja versus alta en sujetos experimentando reincidencia virológica en tratamiento HAART actual.

Propósito: El estudio quiere averiguar si es mejor cambiar medicamentos tan pronto como la carga viral sea El cambiar medicamentos con diferentes cargas virales podría tener importancia en los siguientes términos:

• La capacidad de reparación del sistema imunológico incluso cuando la carga viral no sea completamente suprimida.
• Si el VIH es más o menos propenso a desarrollar resistencia si cambios de medicamentos son retrasados. (Resistencia es determinada cuando algunos de los medicamentos del régimen anti-VIH dejan de funcionar tan bien como antes contra el virus VIH.)

Para más información lláme al 206.731.4718 (Español) o envíe correo electrónico a joaquinp@u.washington.edu.